European Medicines Agency (EU marketing authorisation held by Provepharm), 2011-05-06: EMA record of the EU-wide marketing authorisation for methylthioninium chloride (methylene blue) granted on 6 May 2011, as a prescription-only injection for methaemoglobinaemia, classified as a hybrid medicine.
The European Commission granted a marketing authorisation valid throughout the European Union for Methylthioninium chloride Proveblue on 6 May 2011.
EPAR summary 'Other information about Methylthioninium chloride Proveblue'
European Medicines Agency (EU marketing authorisation held by Provepharm), 2011-05-06: EMA record of the EU-wide marketing authorisation for methylthioninium chloride (methylene blue) granted on 6 May 2011, as a prescription-only injection for methaemoglobinaemia, classified as a hybrid medicine. C16 EMA (foreign regulator). Country: European Union. Status recorded: prescription-only ('can only be obtained with a prescription and must be given by a healthcare professional'); indication 'acute symptomatic treatment of medicinal and chemical products-induced methaemoglobinaemia'; dose 1-2 mg/kg in adults and children over 3 months, 0.3-0.5 mg/kg under 3 months; maximum cumulative dose 7 mg/kg per the SmPC (4 mg/kg in aniline- or dapsone-induced cases); classification: hybrid medicine with Methylthioninium Chloride Injection USP 1% w/v as reference. No EU authorisation exists for cancer, cognitive or wellness use. Bears against the claim that methylene blue's regulatory position is a US-only artefact. Also filed as MTH-038 (claims C16, C7). Study type: regulatory record.
